title: Delivering phage therapy per os: benefits and barriers.
abstract: Multidrug-resistant bacterial infections of the gastrointestinal tract pose a serious public health concern. High levels of antibiotic drug resistance, along with the potential for antibiotics to precipitate disease or alter the gut microbiome has prompted research into alternative treatment methods. Evidence suggests that bacteriophage therapy delivered per os may be well-suited to target such infections. Areas covered: Herein, we discuss the specific advantages and challenges of using orally administered phage therapy. Our literature review encompasses recent works using phages to target various clinically-relevant bacteria in vivo. We also provide insights into methods that aim to overcome the barriers to effective phage transit through the harsh gastrointestinal environment. Expert commentary: Evidence from a number of in vivo animal studies suggests that targeting bacterial infections using phages delivered orally holds potential. Efficacious oral phage therapy depends on the delivery of sufficient phage titers to the infection site, which may be hindered by the host's gastrointestinal tract and immune response.
authors.affiliation: a Institute of Immunology and Experimental Therapy , Polish Academy of Sciences , Wroclaw , Poland.
authors.forename: Susan
authors.initials: S
authors.lastname: Zelasko
authors.affiliation: a Institute of Immunology and Experimental Therapy , Polish Academy of Sciences , Wroclaw , Poland.
authors.forename: Andrzej
authors.initials: A
authors.lastname: Gorski
authors.affiliation: a Institute of Immunology and Experimental Therapy , Polish Academy of Sciences , Wroclaw , Poland.
authors.forename: Krystyna
authors.initials: K
authors.lastname: Dabrowska
mesh_terms: D056704:Adaptive Immunity; D000284:Administration, Oral; D000818:Animals; D001435:Bacteriophages; D024901:Drug Resistance, Multiple, Bacterial; D041981:Gastrointestinal Tract / Q000382:microbiology*; D016905:Gram-Negative Bacterial Infections / Q000276:immunology / Q000382:microbiology / Q000628:therapy*; D016908:Gram-Positive Bacterial Infections / Q000276:immunology / Q000382:microbiology / Q000628:therapy*; D006801:Humans; D000071059:Phage Therapy / Q000379:methods*
keywords: Antibiotic resistance; bacterial infection; bacteriophages; enteropathogenic; gastroenteritis; gastrointestinal tract; gut microbiome; phage therapy